Physician profile
Tojo Thomas
NPI 1497937379
$4,727.95
in general payments reported to CMS, 2019-2025
23 companies · $653 in 2025
The $653 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $700 · 2021: $866 · 2022: $695 · 2023: $648 · 2024: $688 · 2025: $653.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,989.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,988.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,117.86 | 2019-2025 | Mavyret, Linzess, Rinvoq |
| Gilead Sciences, INC. | $621.40 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.95 | 2019-2024 | Xifaxan, Trulance, Plenvu |
| Vivus LLC | $169.79 | 2021-2025 | Pancreaze, Qsymia |
| Nestle Healthcare Nutrition INC. | $153.60 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $141.22 | 2020-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $137.85 | 2019-2023 | Gattex |
| Janssen Biotech, INC. | $131.62 | 2021-2025 | Tremfya, Stelara |
| Ardelyx, INC. | $131.61 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $124.40 | 2024 | |
| Celgene Corporation | $81.11 | 2021-2024 | Zeposia |
| Redhill Biopharma INC. | $76.93 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $71.50 | 2025 | Zenpep |
| Madrigal Pharmaceuticals | $68.90 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $64.87 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alfasigma USA, INC. | $47.58 | 2020 | |
| Phathom Pharmaceuticals, INC. | $45.06 | 2024-2025 | Voquezna |
| Qol Medical, LLC | $39.19 | 2020 | |
| Evoke Pharma, INC. | $33.36 | 2021-2023 | Gimoti |
| Braintree Laboratories, INC. | $30.17 | 2021-2023 | Suflave, Sutab |
| Pfizer INC. | $21.53 | 2025 | |
| Genzyme Corporation | $17.62 | 2022 | |
| Ferring Pharmaceuticals INC. | $12.83 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tojo Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.